We present evidence that a glycolytic enzyme, aldolase, may be a powerful target in anti-cancer therapy and that the disruption of a complex web of intracellular interactions mediated by the enzyme is critical for its anti-cancer action. This evidence concerns the gene HK1 and cancer.